IOVANCE BIOTHERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase (Decrease) in Accrued Liabilities of -$29.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$8.62M.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$21.04M, a 1035.02% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $21.17M, a 418.34% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $5.50M, a 56.70% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $28.64M, a 233.84% increase from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $8.58M, a 56.62% decline from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $19.77M.
- IOVANCE BIOTHERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was -$4.70M, a 122.74% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 63 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$29.65M 10-Q · filed 2026-08-06 | -$8.48M derived: sum of 3 quarters · filed 2026-08-06 | -$2.98M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$21.04M 10-Q · filed 2026-05-07 | $131.00K derived: sum of 2 quarters · filed 2026-05-07 | $5.63M derived: sum of 3 quarters · filed 2026-05-07 | $5.35M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $21.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $26.67M derived: sum of 2 quarters · filed 2026-02-24 | $26.39M derived: sum of 3 quarters · filed 2026-08-06 | $28.64M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.22M derived: sum of 2 quarters · filed 2026-08-06 | $7.47M 10-Q · filed 2025-11-06 | $11.55M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.97M 10-Q · filed 2026-08-06 | $6.05M derived: sum of 3 quarters · filed 2026-08-06 | $18.75M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.25M 10-Q · filed 2026-05-07 | $6.33M derived: sum of 2 quarters · filed 2026-05-07 | $19.04M derived: sum of 3 quarters · filed 2026-05-07 | $33.84M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.79M derived: sum of 2 quarters · filed 2026-02-24 | $31.59M derived: sum of 3 quarters · filed 2026-02-24 | $8.58M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $12.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $27.51M derived: sum of 2 quarters · filed 2025-11-06 | $4.49M 10-Q · filed 2025-11-06 | $13.90M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $14.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$8.21M 10-Q · filed 2025-08-07 | $1.20M derived: sum of 3 quarters · filed 2026-02-24 | $17.13M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$23.02M 10-Q · filed 2025-05-08 | -$13.61M derived: sum of 2 quarters · filed 2026-02-24 | $2.32M derived: sum of 3 quarters · filed 2026-02-24 | $5.81M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $25.34M derived: sum of 2 quarters · filed 2026-02-24 | $28.83M derived: sum of 3 quarters · filed 2026-02-24 | $19.77M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $15.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $19.42M derived: sum of 2 quarters · filed 2024-11-07 | $10.37M 10-Q · filed 2024-11-07 | $11.28M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.56M 10-Q · filed 2024-08-08 | -$4.65M derived: sum of 3 quarters · filed 2025-02-27 | $4.79M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$9.05M 10-Q · filed 2024-05-09 | -$8.14M derived: sum of 2 quarters · filed 2025-02-27 | $1.30M derived: sum of 3 quarters · filed 2025-02-27 | -$8.59M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.35M derived: sum of 2 quarters · filed 2025-02-27 | $461.00K derived: sum of 3 quarters · filed 2025-02-27 | -$4.70M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $9.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$448.00K derived: sum of 2 quarters · filed 2023-11-07 | -$5.61M 10-Q · filed 2023-11-07 | $5.98M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | -$9.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$15.05M 10-Q · filed 2023-08-08 | -$3.46M derived: sum of 3 quarters · filed 2024-02-28 | $5.02M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | -$5.16M 10-Q · filed 2023-05-10 | $6.43M derived: sum of 2 quarters · filed 2024-02-28 | $14.91M derived: sum of 3 quarters · filed 2024-02-28 | $18.79M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $20.07M derived: sum of 2 quarters · filed 2024-02-28 | $23.95M derived: sum of 3 quarters · filed 2024-02-28 | $20.68M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $8.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $12.36M derived: sum of 2 quarters · filed 2022-11-03 | $9.09M 10-Q · filed 2022-11-03 | -$2.05M 10-Q · filed 2021-11-04 | $24.94M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $3.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $611.00K 10-Q · filed 2022-08-04 | -$10.52M 10-Q · filed 2021-08-05 | $16.46M derived: sum of 3 quarters · filed 2023-02-28 | $5.91M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | -$3.27M 10-Q · filed 2022-05-05 | -$14.40M 10-Q · filed 2021-05-06 | $12.59M derived: sum of 2 quarters · filed 2023-02-28 | $2.03M derived: sum of 3 quarters · filed 2023-02-28 | $16.48M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.30M derived: sum of 2 quarters · filed 2023-02-28 | $19.75M derived: sum of 3 quarters · filed 2023-02-28 | $24.11M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.89M derived: sum of 2 quarters · filed 2021-11-04 | $8.26M 10-Q · filed 2021-11-04 | $10.50M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $14.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $18.81M 10-Q · filed 2021-08-05 | $21.05M derived: sum of 3 quarters · filed 2022-02-24 | $23.81M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $4.36M 10-Q · filed 2021-05-06 | $6.61M derived: sum of 2 quarters · filed 2022-02-24 | $9.36M derived: sum of 3 quarters · filed 2022-02-24 | $14.44M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.99M derived: sum of 2 quarters · filed 2022-02-24 | $10.07M derived: sum of 3 quarters · filed 2022-02-24 | $6.73M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.83M derived: sum of 2 quarters · filed 2020-11-05 | $4.49M 10-Q · filed 2020-11-05 | $5.71M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.73M 10-Q · filed 2020-08-06 | $2.96M derived: sum of 3 quarters · filed 2021-02-25 | $4.64M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$3.35M 10-Q · filed 2020-05-05 | -$2.12M derived: sum of 2 quarters · filed 2021-02-25 | -$443.00K derived: sum of 3 quarters · filed 2021-02-25 | $429.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.90M derived: sum of 2 quarters · filed 2021-02-25 | $3.77M derived: sum of 3 quarters · filed 2021-02-25 | $3.23M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $2.55M derived: sum of 2 quarters · filed 2019-11-04 | $2.00M 10-Q · filed 2019-11-04 | $5.22M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $872.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $326.00K 10-Q · filed 2019-08-01 | $3.55M derived: sum of 3 quarters · filed 2020-02-25 | $3.82M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | -$546.00K 10-Q · filed 2018-05-10 | $2.68M derived: sum of 2 quarters · filed 2020-02-25 | $2.95M derived: sum of 3 quarters · filed 2020-02-25 | $4.79M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $3.50M derived: sum of 2 quarters · filed 2020-02-25 | $5.33M derived: sum of 3 quarters · filed 2020-02-25 | $4.55M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.11M derived: sum of 2 quarters · filed 2018-11-06 | $1.33M 10-Q · filed 2018-11-06 | $2.74M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.06M 10-Q · filed 2018-08-07 | $2.47M derived: sum of 3 quarters · filed 2019-02-28 | $1.28M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | -$776.00K 10-Q · filed 2018-05-10 | $633.00K derived: sum of 2 quarters · filed 2019-02-28 | -$552.00K derived: sum of 3 quarters · filed 2019-02-28 | $2.55M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $224.00K derived: sum of 2 quarters · filed 2019-02-28 | $3.33M derived: sum of 3 quarters · filed 2019-02-28 | $3.43M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.92M derived: sum of 2 quarters · filed 2017-11-02 | $2.02M 10-Q · filed 2017-11-02 | |||||
| 2016-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $3.21M 10-Q · filed 2017-08-03 | ||||||
| 2016-03-31 | $104.00K 10-Q · filed 2017-05-03 | |||||||
| 2015-12-31 | $258.00K 10-K · filed 2018-03-12 | |||||||
| 2014-12-31 | -$608.00K 10-K · filed 2017-03-09 | |||||||
| 2012-12-31 | $1.67M 10-K · filed 2013-09-23 | $1.89M 10-K · filed 2013-09-23 | ||||||
| 2012-06-30 | -$250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-23 | $616.00K 10-Q · filed 2013-10-23 | ||||||
| 2012-03-31 | $866.00K 10-Q · filed 2013-10-23 | |||||||
| 2011-12-31 | $70.00K 10-K · filed 2013-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |